-
ZSHK Laboratories Raises RMB 100 Million in Series B Financing Round
•
China-based pre-clinical Contract Research Organization (CRO) ZSHK Laboratories Limited has reportedly raised close to RMB 100 million (USD 13.89 million) in a Series B financing round. The round was led by a fund jointly initiated by AstraZeneca and CICC Capital, with participation from existing investor Ascendum Capital. The proceeds will…
-
Ascentage Pharma Receives Drug Production License for Suzhou Plant
•
Suzhou-based Ascentage Pharma (HKG: 6855) has announced receiving a Drug Production License (A license) following the successful on-site inspection of its global industrial plant. This marks the first such license granted in Suzhou this year, highlighting the company’s significant progress in expanding its manufacturing capabilities. Plant Profile and CapabilitiesThe GMP-…
-
Everest Medicines’ Nefecon Gains Accelerated Approval in Taiwan and South Korea
•
China-based Everest Medicines (HKG: 1952) has announced receiving Accelerated Approval Designation (AAD) from the Taiwan Food and Drug Administration and Orphan Drug Designation (ODD) from the Ministry of Food and Drug Safety in South Korea for its lead product Nefecon (targeted-release budesonide). These designations are for the treatment of primary…
-
Taizhou-Wuxi-Lianyungang Biomedicine Hub Launched at China Medical Expo
•
The 13th China (Taizhou) International Medical Expo witnessed the launch of the Taizhou-Wuxi-Lianyungang national biomedicine hub. This initiative aims to integrate the strengths of three key cities in China’s biomedicine industry, leveraging their unique advantages to drive further growth and innovation. Cities’ Profiles Hub’s PerformanceThe Taizhou-Wuxi-Lianyungang hub can boast over…
-
Huadong Medicine Partners with Dongyang Med for Equity Collaboration
•
China-based Huadong Medicine Co., Ltd (SHE: 000963) has announced an equity collaboration deal with Zhejiang Dongyang Medical Materials Co., Ltd. The partnership aims to strengthen the supply of drugs and medical devices in the city of Dongyang. Financial details of the transaction were not disclosed. Transaction DetailsFollowing the deal, Dongyang…
-
Jiangsu Hengrui Gets NMPA Approval for HR20031 Clinical Study in Type 2 Diabetes
•
China-based Jiangsu Hengrui Pharmaceuticals (SHA: 600276) has announced receiving approval from the National Medical Products Administration (NMPA) to conduct a clinical study for its HR20031 in patients with type 2 diabetes. This marks a significant step forward in the development of a novel treatment option for patients with poorly controlled…
-
Peijia Medical Announces First Patient Implant in MonarQ TTVR System Clinical Study
•
China’s Peijia Medical Limited (HKG: 9996) has announced the first patient implant in a global first-in-man (FIM) clinical study of its MonarQ transcatheter tricuspid valve replacement (TTVR) system. This marks a significant milestone in the development of innovative treatments for tricuspid regurgitation. MonarQ TTVR System ProfileThe MonarQ TTVR system is…
-
Zhejiang Dian Diagnostics Partners with Chengdu Eastern New Area for IVD Hub
•
China-based Zhejiang Dian Diagnostics Co., Ltd (SHE: 300244) has announced a strategic partnership with Chengdu Eastern New Area, focusing on medical diagnosis services, diagnostics development, and other related areas. The collaboration includes plans to establish a domestic in vitro diagnostics (IVD) manufacturing center in the region. Financial details of the…
-
Anyeep Raises RMB 100 Million in Series A Financing for Mass Spectrometry Development
•
Anyeep, a Suzhou-based developer of mass spectrometers, has reportedly raised close to RMB 100 million (USD 13.96 million) in a Series A financing round. The round was led by Greenriver Capital, with participation from Dunhang Investment, PEAKVEST FOF, and existing investors Frees Fund and Yuanbio Venture Capital. The proceeds will…
-
Shanghai Henlius Biotech to Provide R&D Services for COVID-19 Therapy Azvudine
•
China-based Shanghai Henlius Biotech (HKG: 2696) has entered into an agreement to provide clinical study research and development (R&D) services for the COVID-19 therapy azvudine to compatriot firms HeNan Genuine Biotech Co., Ltd and Shanghai Fosun Pharmaceutical Development Co., Ltd. The services will focus on COVID-19 prevention and include clinical…
-
China Resources Double-Crane Gains Approval for Definity in China
•
China Resources Double-Crane Pharmaceutical Co., Ltd (SHA: 600062) has announced receiving market approval from the National Medical Products Administration (NMPA) to act as the domestic agent for Definity (perflutren lipid microsphere injection). The contrast agent can now be used to enhance the recognition of the left ventricular endocardial boundary when…
-
XtalPi Partners with CK Life Sciences to Develop AI Cancer Vaccine Platform
•
Sino-US artificial intelligence (AI) firm XtalPi Inc. has struck a partnership with China-based CK Life Sciences to develop an AI cancer vaccine research and development (R&D) platform. The collaboration aims to leverage the respective strengths of both companies to advance the development of AI-driven cancer vaccines. Financial details of the…
-
Bliss Bio’s BB-1709 Accepted for Review by China’s CDE
•
Hangzhou-based oncology-focused clinical stage biotech Bliss Bio has announced that its clinical filing for the Category 1 therapeutic biologic product injectable BB-1709 has been accepted for review by the Center for Drug Evaluation (CDE). This marks a significant milestone in the development of BB-1709, a potential first-in-class antibody drug conjugate…
-
Xiling Lab Raises RMB 100 Million for ADC Development and IND Filing
•
Xiling Lab, a Chengdu-based drug developer specializing in catalytic synthesis technology, has reportedly raised close to RMB 100 million (USD 13.96 million) in a Pre-Series B financing round. Investors included Chengdu Bio City No. 1 Equity Investment Fund, Chengdu Gaoxin New Economy Venture Capital, Pengzhou Global Biomedical Technology Achievement Transformation…
-
PrimeLink Bio Raises Funds for ADC Development and R&D Expansion
•
Shenzhen-based drug developer PrimeLink Bio has reportedly raised “hundreds of millions” of renminbi in a new financing round led by Vertex Ventures. Fosun Pharma and Kaitai Capital also participated in the round. The proceeds will be used to support technology research and development (R&D), talent recruitment, and laboratory construction. Company…
-
AnchorDx’s UriFind Receives Breakthrough Therapy Designation for Urothelial Carcinoma
•
China-based Guangzhou AnchorDx Medical Co., Ltd, a specialist in methylation high-throughput sequencing, has obtained a breakthrough therapy designation for its urothelial carcinoma (UC) early diagnostic product UriFind. This marks the first such designation for a Chinese product in this category. The urine DNA methylation detection is being fast-tracked for approval…
-
Visen Pharmaceuticals Files for Hong Kong IPO with Focus on Growth Hormone
•
Visen Pharmaceuticals, a China-based joint venture between Denmark-headquartered Ascendis Pharma and Chinese healthcare-focused investment firm Vivo Capital, has filed for an initial public offering (IPO) with the Hong Kong Stock Exchange. Morgan Stanley and Jefferies are acting as co-sponsors. The proceeds will be used to support research and development (R&D)…
-
Junshi Biosciences Files for UK Approval of PD-1 Inhibitor Tuoyi
•
China-based Junshi Biosciences (HKG: 1877, SHA: 688180) has announced that it has filed for market approval with the Medicines and Healthcare products Regulatory Agency (MHRA) of the UK for its programmed death-1 (PD-1) inhibitor Tuoyi (toripalimab). The filing seeks approval for the checkpoint inhibitor in combination with chemotherapy as a…
-
CSPC Pharmaceutical Reports Q3 2022 Financials with 13.8% Revenue Growth
•
China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has released its Q3 2022 financial results, reporting a 13.8% year-on-year (YOY) increase in revenues to RMB 23.496 billion (USD 2.87 billion). The growth was driven by increases across multiple business segments, including on-patent medicines, raw material products, and functional food. Revenue Breakdown…
-
Tianjin Tianyao Fined for Anti-Monopoly Violations in Carmustine Sales
•
China-based Tianjin Tianyao Pharmaceutical Co., Ltd (SHA: 600488) has been fined RMB 27.72 million (USD 3.77 million) by the Tianjin Administration for Market Regulation. The fine was imposed for the “abuse of market domination of carmustine in China by selling the product at an unfairly high price,” which violates Item…
